Lineage Cell Therapeutics to Present at Raymond James 2021 Human Health Innovation Conference on June 22, 2021
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021, at 1:20 p.m. ET. Investors can access the presentation live and archived on the company's Events and Presentations webpage. Lineage develops allogeneic cell therapies targeting significant medical needs, with products like OpRegen, OPC1, and VAC2 currently in Phase 1/2a clinical trials.
- None.
- None.
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, announced today that Brian M. Culley, Chief Executive Officer, will be presenting at the Raymond James 2021 Human Health Innovation Conference being held virtually on June 22, 2021 at 1:20 p.m. Eastern Time / 10:20 a.m. Pacific Time. Interested investors can access the live and archived webcasts on the Events and Presentations section of Lineage’s website. Additional videos are available on the Media page of the Lineage website.
About Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC2, an allogeneic dendritic cell therapy produced from Lineage’s VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1 clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210615005498/en/
FAQ
When is Lineage Cell Therapeutics presenting at the Raymond James 2021 Human Health Innovation Conference?
How can I access the presentation by Brian M. Culley at the conference?
What are the key products being developed by Lineage Cell Therapeutics?
What is the stock symbol for Lineage Cell Therapeutics?
What areas do Lineage Cell Therapeutics' clinical programs target?
